Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Describe sex differences in outcomes and response to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF). Background: HFpEF affects women more frequently than men. Sex differences in effect of mineralocorticoid antagonists have not been reported. Methods: This was an exploratory, post-hoc, non-prespecified analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). Subjects with symptomatic HF and an LVEF ≥45% were randomized to spironolactone or placebo. Subjects enrolled from the Americas were analyzed. The primary outcome was a composite of cardiovascular (CV) death, cardiac arrest, or HF hospitalization. Secondary outcomes included all-cause, CV, and non-CV mortality, and CV, HF, and non-CV hospitalization. Sex differences in outcomes and treatment effect were determined using time-to-event analysis. Results: In total, 882/1767 (49.9%) subjects were women. Women were older with fewer comorbidities but worse patient-reported outcomes. There were no sex differences in outcomes in the placebo arm or in response to spironolactone for the primary outcome or its components. Spironolactone was associated with reduced all-cause mortality in women (HR 0.66, p=0.01), but not in men (pinteraction=0.02). Conclusions: In TOPCAT, women and men presented with different clinical profiles and similar clinical outcomes. The interaction between spironolactone and sex in TOPCAT overall and in our analysis was non-significant for the primary outcome, but there was a reduction in all-cause mortality associated with spironolactone in women with a significant interaction. Prospective evaluation is needed to determine whether spironolactone may be effective for treatment of HFpEF in women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Renin angiotensin system and gender differences in the cardiovascular system
Fischer, M. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00479-5 · Cited by 384
Cited by
Sex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes
Regitz-Zagrosek, V., & Gebhard, C. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00797-4 · Cited by 386
Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab798 · Cited by 264
Packer, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1902 · Cited by 185
Sorimachi, H., Obokata, M., Takahashi, N., Reddy, Y. N. V., Jain, C. C., Verbrugge, F. H., Koepp, K. E., Khosla, S., Jensen, M. D., & Borlaug, B. A. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa823 · Cited by 183
Metadata
- Authors
- Merrill, M., Sweitzer, N. K., Lindenfeld, J., & Kao, D. P.
- Venue
- JACC: Heart Failure
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 7
- Issue
- 3
- Pages
- 228-238
- ISSN
- 2213-1779 (ISSN-L)
- OpenAlex
- W2915837534
- Cited by
- 201
- References
- 6
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction. https://app.cochat.ai/papers/10.1016/j.jchf.2019.01.003
- The paper
- Merrill, M., Sweitzer, N. K., Lindenfeld, J., & Kao, D. P. (2019). Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2019.01.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.